Literature DB >> 22270997

Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection.

Amanda M Laird1, Paul G Gauger, Barbra S Miller, Gerard M Doherty.   

Abstract

BACKGROUND: Prophylactic central lymph node dissection (CLND) accompanying total thyroidectomy for papillary thyroid cancer (PTC) remains controversial. Our hypothesis is that CLND may help select patients who benefit from postoperative radioactive iodine (RAI).
METHODS: A total of 119 patients who were clinically node-negative underwent total thyroidectomy/bilateral CLND for papillary thyroid cancer (PTC) > 1 cm during 2002-2010. Pathology results, RAI results, and outcomes were compared between node-positive (NP) and node-negative (NN) patients.
RESULTS: NP and NN patients were similar in age, gender, tumor size, and MACIS score. Median number of nodes excised was six. The rate of permanent hypocalcemia was 1.7% without permanent recurrent laryngeal nerve injuries. Thirteen of 52 (25%) NN patients and 24 of 67 (36%) NP patients had suspicious nodes by intraoperative inspection. The node assessment negative predictive value was 75%; positive predictive value was 36%. Fifty-six percent (67/118) were NP; 100 patients were treated with RAI. Fourteen of 62 NP patients had abnormal postoperative RAI scans aside from the thyroid remnant versus 4 of 38 NN patients (23 vs. 11%, p = 0.18). Median 1-year stimulated thyroglobulin (Tg) level was 0.0 for both (range 0.0-1.2, NN; 0.0-22.7, NP; p = 0.1). NP patients received higher doses of RAI (150 vs. 30 mCi, p < 0.001). Rate of recurrent or persistent disease was 3.4%.
CONCLUSIONS: Few node-negative patients have abnormal RAI scans outside of the thyroid bed. Node-positive patients had greater variability in stimulated 1-year Tg levels after higher doses of RAI. CLND may identify the patients most likely to have persistently elevated stimulated Tg after initial therapy for PTC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22270997     DOI: 10.1007/s00268-012-1431-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  27 in total

1.  Preservation of the recurrent laryngeal nerves in thyroid and parathyroid reoperations.

Authors:  J F Moley; T C Lairmore; G M Doherty; L M Brunt; M K DeBenedetti
Journal:  Surgery       Date:  1999-10       Impact factor: 3.982

2.  Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit.

Authors:  Wen T Shen; Lauren Ogawa; Daniel Ruan; Insoo Suh; Quan-Yang Duh; Orlo H Clark
Journal:  Surgery       Date:  2010-05-07       Impact factor: 3.982

3.  Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer.

Authors:  David T Hughes; Matthew L White; Barbra S Miller; Paul G Gauger; Richard E Burney; Gerard M Doherty
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

Review 4.  Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone.

Authors:  Edward J Chisholm; Elena Kulinskaya; Neil S Tolley
Journal:  Laryngoscope       Date:  2009-06       Impact factor: 3.325

5.  Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.

Authors:  Catharina Ihre Lundgren; Per Hall; Paul W Dickman; Jan Zedenius
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

6.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

7.  Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis.

Authors:  Tarek Zetoune; Xavier Keutgen; Daniel Buitrago; Hasan Aldailami; Huibo Shao; Madhu Mazumdar; Thomas J Fahey; Rasa Zarnegar
Journal:  Ann Surg Oncol       Date:  2010-07-02       Impact factor: 5.344

8.  Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer.

Authors:  Mark Sywak; Lachlan Cornford; Paul Roach; Peter Stalberg; Stan Sidhu; Leigh Delbridge
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

9.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.

Authors:  Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

10.  Consensus statement on the terminology and classification of central neck dissection for thyroid cancer.

Authors:  Sally E Carty; David S Cooper; Gerard M Doherty; Quan-Yang Duh; Richard T Kloos; Susan J Mandel; Gregory W Randolph; Brendan C Stack; David L Steward; David J Terris; Geoffrey B Thompson; Ralph P Tufano; R Michael Tuttle; Robert Udelsman
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

View more
  7 in total

1.  Quantification of lymph nodes in the central compartment of the neck: a cadaveric study.

Authors:  Enyinnaya Ofo; Selvam Thavaraj; Daron Cope; James Barr; Karan Kapoor; Jean-Pierre Jeannon; Richard Oakley; Claire Lock; Edward Odell; Ricard Simo
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-20       Impact factor: 2.503

Review 2.  Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Juan J Sancho; Thomas W Jay Lennard; Ivan Paunovic; Frédéric Triponez; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2013-12-19       Impact factor: 3.445

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Naoyoshi Onoda; Hitoshi Noguchi; Akira Yoshida
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

5.  The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.

Authors:  Mehmet Hakan Korkmaz; Bülent Öcal; Güleser Saylam; Erman Çakal; Ömer Bayır; Esra Tutal; Emel Çadallı Tatar
Journal:  Langenbecks Arch Surg       Date:  2017-02-21       Impact factor: 3.445

6.  Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma.

Authors:  Dana M Hartl; Elisabeth Mamelle; Isabelle Borget; Sophie Leboulleux; Haïtham Mirghani; Martin Schlumberger
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

7.  Prophylactic "First-Step" Central Neck Dissection (Level 6) Does Not Increase Morbidity After (Total) Thyroidectomy.

Authors:  Andreas Selberherr; Philipp Riss; Christian Scheuba; Bruno Niederle
Journal:  Ann Surg Oncol       Date:  2016-07-08       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.